to § 225.25(b)(1) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System, March 22, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95–7521 Filed 3–27–95; 8:45 am]

BILLING CODE 6210–01–F

Otis Truman Arnold, et al.; Change in Bank Control Notices; Acquisitions of Shares of Banks or Bank Holding Companies

The notificants listed below have applied under the Change in Bank Control Act (12 U.S.C. 1817(j)) and § 225.41 of the Board's Regulation Y (12 CFR 225.41) to acquire a bank or bank holding company. The factors that are considered in acting on the notices are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The notices are available for immediate inspection at the Federal Reserve Bank indicated. Once the notices have been accepted for processing, they will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing to the Reserve Bank indicated for that notice or to the offices of the Board of Governors. Comments must be received not later than April 11, 1995.

A. Federal Reserve Bank of Dallas (Genie D. Short, Vice President) 2200 North Pearl Street, Dallas, Texas 75201-2272:

1. Otis Truman and Anita Ray Arnold, both of Texarkana, Texas; to acquire a total of 49.1 percent of the voting shares of New Boston Bancshares, Inc., New Boston, Texas, and thereby indirectly acquire First National Bank of New Boston, New Boston, Texas.

B. Federal Reserve Bank of San Francisco (Kenneth R. Binning, Director, Bank Holding Company) 101 Market Street, San Francisco, California 94105:

1. James Lester Ryan, Orinda, California; to acquire an additional 2.32 percent, for a total of 10.65 percent, of the voting shares of BWC Corp., Walnut Creek, California, and thereby indirectly acquire Bank of Walnut Creek, Walnut Creek, California.

Board of Governors of the Federal Reserve System, March 22, 1995.

Jennifer J. Johnson,

Deputy Secretary of the Board.

[FR Doc. 95–7519 Filed 3–27–95; 8:45 am]

BILLING CODE 6210–01–F

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Board of Scientific Counselors, National Institute for Occupational Safety and Health; Meeting

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), the Centers for Disease Control and Prevention (CDC), announces the following committee meeting.

Name: Board of Scientific Counselors, National Institute for Occupational Safety and Health (BSC, NIOSH).

Time and Date: 10 a.m.–5 p.m., April 12, 1995.

Place: The Washington Court Hotel, Ash Room, 525 New Jersey Avenue, NW, Washington, DC 20001

Status: Closed 10 a.m.–12 noon; Open 1 p.m.–5 p.m.

Purpose: The Board reviews research activities to provide guidance on the quality, timeliness, and efficacy of the Institute's programs.

Matters To Be Discussed: The agenda will include personnel and organizational issues relating to the reorganization of NIOSH. The meeting will convene in closed session from 10 a.m. to 12 noon to discuss subject matter relating solely to the internal personnel rules and practices of NIOSH. This portion of the meeting will be closed to the public in accordance with the provisions set forth in section 552b(c)(2), title 5 U.S.C., and the Determination of the Associate Director for Management and Operations, CDC, pursuant to Pub. L. 92–463. The open portion of the meeting will include a report from the Director of NIOSH, a toxicology report, an extramural report, and future activities of the Board.

Agenda items are subject to change as priorities dictate.

Contact Person for More Information: Richard A. Lemen, Ph.D., Executive Secretary, BSC, NIOSH, and Deputy Director, NIOSH, CDC, 1600 Clifton Road NE., Mailstop D–35, Atlanta, Georgia 30333, telephone 404/639–3773.

Dated: March 22, 1995.

Jack Jackson,

Associate Director for Management and Operations, Centers for Disease Control and Prevention (CDC).

[FR Doc. 95–7579 Filed 3–27–95; 8:45 am]

BILLING CODE 4163–19–M

Food and Drug Administration

[Docket No. 94D–0407]

Miscellaneous Compliance Policy Guides; Revocation

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the revocation of two compliance policy guides (CPG's) because they are outdated. This action is being taken to ensure that FDA's CPG's are accurate and current.

DATES: Effective March 28, 1995.

FOR FURTHER INFORMATION CONTACT: Judith A. Gushee, Center for Veterinary Medicine (HFV–236), Food and Drug Administration, 7500 Standish Place, Rockville, MD 20855, 301–594–1785.

SUPPLEMENTARY INFORMATION: FDA is revoking the following CPG's because they are outdated:

(1) CPG 7126.06 ''State Analysis of Animal Feed for Protein, Fat, and Fiber Content,'' and

(2) CPG 7126.14 ''Protein in Animal Feeds.''

These CPG's were intended to assist the States in enforcing their requirements for guaranteed analysis labeling claims when their regulatory authority was insufficient. However, State regulatory authority is sufficient, and the States have not required use of these CPG's for a number of years. Futhermore, if FDA regulatory action is required, the agency has ample authority. Therefore, FDA is revoking CPG's 7126.06 and 7126.14 because they are outdated.

Dated: March 13, 1995.

Gary Dykstra,

Acting Associate Commissioner for Regulatory Affairs.

[FR Doc. 95–7615 Filed 3–27–95; 8:45 am]

BILLING CODE 4160–01–F

[Docket No. 94D–0356]

Protocol Development for Clinical Effectiveness and Target Animal Safety Trials; Availability of Guideline

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of the guideline entitled, ''Protocol Development Guideline for Clinical Effectiveness and Target Animal Safety Trials'' prepared by the Center for Veterinary Medicine (CVM). This guideline describes a suggested systematic approach to be followed when designing and reporting effectiveness and target animal safety studies that are conducted to provide data to support animal drug approvals.

DATES: Written comments may be submitted at any time.